Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

This study has been terminated.
(This study has been terminated for administrative reasons only.)
Sponsor:
Information provided by (Responsible Party):
TauRx Therapeutics Ltd
ClinicalTrials.gov Identifier:
NCT01626391
First received: June 20, 2012
Last updated: June 10, 2014
Last verified: June 2014
Results First Received: April 28, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
TRx0237 One 125-mg TRx0237 tablet administered twice daily (250 mg/day TRx0237)
Placebo One placebo tablet containing 4-mg TRx0237 administered twice daily (8 mg/day TRx0237)

Participant Flow:   Overall Study
    TRx0237     Placebo  
STARTED     5     4  
COMPLETED     3     4  
NOT COMPLETED     2     0  
Physician Decision                 1                 0  
Withdrawal by Subject                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Population

Reporting Groups
  Description
TRx0237 One 125-mg TRx0237 tablet administered twice daily (250 mg/day TRx0237)
Placebo One placebo tablet containing 4-mg TRx0237 administered twice daily (8 mg/day TRx0237)
Total Total of all reporting groups

Baseline Measures
    TRx0237     Placebo     Total  
Number of Participants  
[units: participants]
  5     4     9  
Age  
[units: years]
Mean ± Standard Deviation
  74.2  ± 8.7     74.3  ± 3.3     74.2  ± 6.5  
Gender  
[units: participants]
     
Female     3     2     5  
Male     2     2     4  
Race (NIH/OMB)  
[units: participants]
     
American Indian or Alaska Native     0     0     0  
Asian     0     0     0  
Native Hawaiian or Other Pacific Islander     0     0     0  
Black or African American     0     0     0  
White     5     4     9  
More than one race     0     0     0  
Unknown or Not Reported     0     0     0  
Ethnicity (NIH/OMB)  
[units: participants]
     
Hispanic or Latino     0     0     0  
Not Hispanic or Latino     5     4     9  
Unknown or Not Reported     0     0     0  
Region of Enrollment  
[units: participants]
     
United Kingdom     5     4     9  
Anti-dementia Therapy  
[units: participants]
     
AChEI     5     4     9  
Memantine     0     0     0  
Both     0     0     0  



  Outcome Measures

1.  Primary:   Safety and Tolerability of TRx0237 When Coadministered With an Acetylcholinesterase Inhibitor (AChEI) and/or Memantine   [ Time Frame: 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination leading to small numbers of subjects analyzed


  More Information